Emergent BioSolutions Inc

Emergent BioSolutions Inc(EBS)资讯与事件

$5.910

-0.030 (-0.51%)收盘时

EBS 资讯

EBS 事件

8/31 08:00

Emergent BioSolutions Awarded Narcan Nasal Spray Contract by Canadian Government

Emergent BioSolutions announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply Narcan Nasal Spray. The standing offer is effective from October 1 through September 30, 2029, with an option to extend for an additional two years. Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated public sector organizations across Canada may procure Narcan Nasal Spray through individual call-ups.

8/11 10:00

Trump Signs Vaccine Executive Order Impacting Multiple Companies

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.VACCINE EO:President Donald Trump signed an executive order proposing to split the MMR vaccine into separate shots, require separate vaccination visits, and overhaul national childhood immunization recommendations into three categories, Bloomberg's Rachel Cohrs Zhang, Jessica Nix, and Josh Wingrove. "There's a reason for such epidemic rates of autism, and we're going to bring it back to much closer to where it was," the president said. "While we do not know exactly what the cause is with respect to autism, it is essential to our research efforts that we have the very best vaccine recommendations in the entire world." Scientific evidence has shown no link between autism and childhood vaccines, and decades of research have failed to identify a singular cause of autism, Bloomberg notes. Publicly traded companies that make vaccines include Johnson & Johnson, Pfizer, BioNTech, Moderna, Novavax, GSK, AstraZeneca, and Emergent BioSolutions.OPENAI, WHITE HOUSE RELATIONSHIP:OpenAI executive Dean Ball's public clash with Trump administration officials over AI regulation has strained the company's relationship with the White House, with officials warning that his hiring could further damage ties, The New York Post's Thomas Barrabi.JONES ACT WAIVER:President Donald Trump has extended a waiver of the Jones Act and narrowed the scope, allowing foreign ships to transport oil and other commodities around the U.S. for 90 more days with new limits, according to Bloomberg, citing a White House official.FUNDING AWARD:Stratasyshas been awarded $7.8M of funding through The 2026 America Makes and the Department of War Organic Industrial Base Modernization Challenge that focuses on advancing additive manufacturing and related technologies to support defense manufacturing modernization. The 24-month award will support development of on-site quality assurance capabilities for Stratasys' F3300 and F900 industrial FDM platforms. This will enable manufacturers to generate the real-time process data needed to scale additive manufacturing production, expand capacity and reduce reliance on costly post-build inspection and qualification.

8/10 16:00

Trump Signs Executive Order to Restructure Vaccination Protocols

President Donald Trump signed an executive order proposing to split the MMR vaccine into separate shots, require separate vaccination visits, and overhaul national childhood immunization recommendations into three categories, Bloomberg's Rachel Cohrs Zhang, Jessica Nix, and Josh Wingrove report. "There's a reason for such epidemic rates of autism, and we're going to bring it back to much closer to where it was," the president said. "While we do not know exactly what the cause is with respect to autism, it is essential to our research efforts that we have the very best vaccine recommendations in the entire world." Scientific evidence has shown no link between autism and childhood vaccines, and decades of research have failed to identify a singular cause of autism, Bloomberg notes. Publicly traded companies that make vaccines include Johnson & Johnson (JNJ), Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), Novavax (NVAX), GSK (GSK), AstraZeneca (AZN), and Emergent BioSolutions (EBS).

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始